These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 23567655)

  • 1. Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study.
    Freedland SJ; Hamilton RJ; Gerber L; Banez LL; Moreira DM; Andriole GL; Rittmaster RS
    Prostate Cancer Prostatic Dis; 2013 Sep; 16(3):254-9. PubMed ID: 23567655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial.
    Muller RL; Gerber L; Moreira DM; Andriole G; Castro-Santamaria R; Freedland SJ
    Eur Urol; 2012 Nov; 62(5):757-64. PubMed ID: 22658758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic syndrome-like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study.
    Sourbeer KN; Howard LE; Andriole GL; Moreira DM; Castro-Santamaria R; Freedland SJ; Vidal AC
    BJU Int; 2015 May; 115(5):736-43. PubMed ID: 24931061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.
    Marberger M; Freedland SJ; Andriole GL; Emberton M; Pettaway C; Montorsi F; Teloken C; Rittmaster RS; Somerville MC; Castro R
    BJU Int; 2012 Apr; 109(8):1162-9. PubMed ID: 21699645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study.
    Vidal AC; Howard LE; Moreira DM; Castro-Santamaria R; Andriole GL; Freedland SJ
    Clin Cancer Res; 2015 Feb; 21(4):756-62. PubMed ID: 25520389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The associations between statin use and prostate cancer screening, prostate size, high-grade prostatic intraepithelial neoplasia (PIN), and prostate cancer.
    Fowke JH; Motley SS; Barocas DA; Cookson MS; Concepcion R; Byerly S; Smith JA
    Cancer Causes Control; 2011 Mar; 22(3):417-26. PubMed ID: 21170754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study.
    Jamnagerwalla J; Howard LE; Allott EH; Vidal AC; Moreira DM; Castro-Santamaria R; Andriole GL; Freeman MR; Freedland SJ
    Prostate Cancer Prostatic Dis; 2018 Jun; 21(2):252-259. PubMed ID: 29282360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial.
    Roehrborn CG; Andriole GL; Wilson TH; Castro R; Rittmaster RS
    Eur Urol; 2011 Feb; 59(2):244-9. PubMed ID: 21093145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statin use and longitudinal changes in prostate volume; results from the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
    Allott EH; Csizmadi I; Howard LE; Muller RL; Moreira DM; Andriole GL; Roehrborn CG; Freedland SJ
    BJU Int; 2020 Feb; 125(2):226-233. PubMed ID: 31479563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alcohol intake increases high-grade prostate cancer risk among men taking dutasteride in the REDUCE trial.
    Fowke JH; Howard L; Andriole GL; Freedland SJ
    Eur Urol; 2014 Dec; 66(6):1133-8. PubMed ID: 24568894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of Screening for Prostate Cancer Among Men Who Use Statins.
    Vettenranta A; Murtola TJ; Raitanen J; Raittinen P; Talala K; Taari K; Stenman UH; Tammela TLJ; Auvinen A
    JAMA Oncol; 2022 Jan; 8(1):61-68. PubMed ID: 34817559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study.
    Andriole GL; Bostwick D; Brawley OW; Gomella L; Marberger M; Montorsi F; Pettaway C; Tammela TL; Teloken C; Tindall D; Freedland SJ; Somerville MC; Wilson TH; Fowler I; Castro R; Rittmaster RS;
    J Urol; 2011 Jan; 185(1):126-31. PubMed ID: 21074214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of dutasteride on the risk of prostate cancer.
    Andriole GL; Bostwick DG; Brawley OW; Gomella LG; Marberger M; Montorsi F; Pettaway CA; Tammela TL; Teloken C; Tindall DJ; Somerville MC; Wilson TH; Fowler IL; Rittmaster RS;
    N Engl J Med; 2010 Apr; 362(13):1192-202. PubMed ID: 20357281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride.
    Andriole GL; Marberger M; Roehrborn CG
    J Urol; 2006 May; 175(5):1657-62. PubMed ID: 16600723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer.
    Ross AE; Feng Z; Pierorazio PM; Landis P; Walsh PC; Carter HB; Trock BJ; Schaeffer EM
    BJU Int; 2012 Sep; 110(5):651-7. PubMed ID: 22289613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dutasteride treatment over 2 years delays prostate-specific antigen progression in patients with biochemical failure after radical therapy for prostate cancer: results from the randomised, placebo-controlled Avodart After Radical Therapy for Prostate Cancer Study (ARTS).
    Schröder F; Bangma C; Angulo JC; Alcaraz A; Colombel M; McNicholas T; Tammela TL; Nandy I; Castro R
    Eur Urol; 2013 May; 63(5):779-87. PubMed ID: 23176897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
    Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
    Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The risk of prostate cancer for men on aspirin, statin or antidiabetic medications.
    Nordström T; Clements M; Karlsson R; Adolfsson J; Grönberg H
    Eur J Cancer; 2015 Apr; 51(6):725-33. PubMed ID: 25727881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
    Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
    Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statin Use and Lower Urinary Tract Symptoms Incidence and Progression in Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial.
    Kramer JJ; Gu L; Moreira D; Andriole G; Csizmadi I; Freedland SJ
    J Urol; 2022 Feb; 207(2):417-423. PubMed ID: 34544265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.